Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report

Int J Dermatol. 2022 Jul;61(7):e267-e269. doi: 10.1111/ijd.15834. Epub 2021 Aug 7.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Immunological / therapeutic use
  • Brentuximab Vedotin* / therapeutic use
  • Humans
  • Immunoconjugates* / therapeutic use
  • Ki-1 Antigen
  • Lymphoma, Large-Cell, Anaplastic* / diagnosis
  • Lymphoma, Large-Cell, Anaplastic* / drug therapy
  • Lymphoma, Large-Cell, Anaplastic* / pathology

Substances

  • Antineoplastic Agents, Immunological
  • Immunoconjugates
  • Ki-1 Antigen
  • Brentuximab Vedotin

Grants and funding